GlassScriptPhysician profile
Alexander Alvarez
NPI 1841334976
$5,042.41
in general payments reported to CMS, 2019-2025
23 companies · $859 in 2025
The $859 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $517 · 2022: $768 · 2023: $1,556 · 2024: $1,341 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,692 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,692.20 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,424.84 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,027.30 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $661.76 | 2021-2025 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $203.78 | 2024-2025 | Auvelity |
| Lilly USA, LLC | $199.18 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $171.23 | 2023-2025 | |
| Astellas Pharma US INC | $156.33 | 2023-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $153.62 | 2023-2025 | Rexulti |
| Pfizer INC. | $142.98 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $138.85 | 2023-2024 | Winrevair, Verquvo |
| Abbvie INC. | $138.32 | 2023-2024 | |
| Eisai INC. | $121.95 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $102.87 | 2022-2024 | |
| Vanda Pharmaceuticals INC. | $76.02 | 2023 | Hetlioz |
| Amgen INC. | $72.35 | 2025 | Otezla, Repatha |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.04 | 2023-2025 | Jardiance |
| Abbott Laboratories | $49.26 | 2022-2023 | Proclaim |
| Amarin Pharma, INC. | $37.60 | 2022 | |
| Optinose US, INC. | $22.97 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.53 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.12 | 2024 | Voquezna |
| Exact Sciences Corporation | $16.07 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $14.44 | 2023 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.